Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports

被引:88
作者
Bailes, Julian [1 ]
Soloviev, Mikhail [1 ]
机构
[1] Royal Holloway Univ London, Dept Biol Sci, London TW20 0EX, England
关键词
insulin-like growth factor; IGF; IGFBP; IGF-1R; IGF-2R; IGFBP-rP; IGFBPL1; ALS; insulin; doping; FACTOR-BINDING-PROTEIN; PROSTATE-CANCER RISK; ACID-LABILE SUBUNIT; MGF E-PEPTIDE; ASSAY METHODOLOGIES; FACTOR (IGF)-I; EWING SARCOMA; HORMONE; EXPRESSION; RECEPTOR;
D O I
10.3390/biom11020217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Insulin-like growth factor-1 (IGF-1) is the principal mediator of growth hormone (GH), plays a crucial role in promoting cell growth and differentiation in childhood and continues to have an anabolic effect in adults. IGF-1 is part of a wide network of growth factors, receptors and binding proteins involved in mediating cellular proliferation, differentiation and apoptosis. Bioavailability of IGF-1 is affected by insulin-like growth factor binding proteins (IGFBPs) which bind IGF-1 in circulation with an affinity equal to or greater than that of the IGF-1 receptor (IGF-1R). The six IGFBPs serve as carrier proteins and bind approximately 98% of all circulating IGF-1. Other proteins known to bind IGF-1 include ten IGFBP-related proteins (IGFBP-rPs), albeit with lower affinities than the IGFBPs. IGF-1 expression levels vary in a number of clinical conditions suggesting it has the potential to provide crucial information as to the state of an individual's health. IGF-1 is also a popular doping agent in sport and has featured in many high-profile doping cases in recent years. However, the existence of IGFBPs significantly reduces the levels of immunoreactive IGF-1 in samples, requiring multiple pre-treatment steps that reduce reproducibility and complicates interpretation of IGF-1 assay results. Here we provide an overview of the IGF network of growth factors, their receptors and the entirety of the extended family of IGFBPs, IGFBP-rPs, E peptides as well as recombinant IGF-1 and their derivatives. We also discuss issues related to the detection and quantification of bioavailable IGF-1.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 118 条
[1]   The intrinsically disordered E-domains regulate the IGF-1 prohormones stability, subcellular localisation and secretion [J].
Annibalini, Giosue ;
Contarelli, Serena ;
De Santi, Mauro ;
Saltarelli, Roberta ;
Di Patria, Laura ;
Guescini, Michele ;
Villarini, Anna ;
Brandi, Giorgio ;
Stocchi, Vilberto ;
Barbieri, Elena .
SCIENTIFIC REPORTS, 2018, 8
[2]   Preferential Expression of IGF-1Ec (MGF) Transcript in Cancerous Tissues of Human Prostate: Evidence for a Novel and Autonomous Growth Factor Activity of MGF E Peptide in Human Prostate Cancer Cells [J].
Armakolas, Athanasios ;
Philippou, Anastassios ;
Panteleakou, Zacharoula ;
Nezos, Adrianos ;
Sourla, Antigone ;
Petraki, Constantina ;
Koutsilieris, Michael .
PROSTATE, 2010, 70 (11) :1233-1242
[3]   Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance [J].
Ashare, Alix ;
Nymon, Amanda B. ;
Doerschug, Kevin C. ;
Morrison, John M. ;
Monick, Martha M. ;
Hunninghake, Gary W. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (02) :149-157
[4]   Targeting insulin-like growth factor type 1 receptor in cancer therapy [J].
Atzori, Francesco ;
Traina, Tiffany A. ;
Ionta, Maria Teresa ;
Massidda, Bruno .
TARGETED ONCOLOGY, 2009, 4 (04) :255-266
[5]  
Ballard FJ, 1996, INT J BIOCHEM CELL B, V28, P1085
[6]   The IGF-I receptor in cancer research [J].
Baserga, R .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :1-6
[7]   The decline and fall of the IGF-I receptor [J].
Baserga, Renato .
JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (04) :675-679
[9]   RADIOIMMUNOASSAY OF GROWTH-HORMONE DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN IN HUMAN-PLASMA [J].
BAXTER, RC ;
MARTIN, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1504-1512
[10]   IGF binding proteins in cancer: mechanistic and clinical insights [J].
Baxter, Robert C. .
NATURE REVIEWS CANCER, 2014, 14 (05) :329-341